

## Product datasheet for **AP20490PU-N**

### MLH1 Rabbit Polyclonal Antibody

#### Product data:

Product Type:	Primary Antibodies
Applications:	IF, WB
Recommended Dilution:	<b>Western blot:</b> 1/500-1/1000. <b>Immunofluorescence:</b> 1/50-1/200.
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Clonality:	Polyclonal
Immunogen:	Synthetic peptide, corresponding to amino acids 450-500 of Human MLH1.
Specificity:	This antibody detects endogenous levels of MLH1 protein. (region surrounding Ser467)
Formulation:	Phosphate buffered saline (PBS), pH 7.2. State: Aff - Purified State: Liquid purified Ig fraction (> 95% pure by SDS-PAGE) Preservative: 0.05% Sodium Azide
Concentration:	1.0 mg/ml
Purification:	Affinity Chromatography using epitope-specific immunogen
Conjugation:	Unconjugated
Storage:	Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing.
Stability:	Shelf life: one year from despatch.
Predicted Protein Size:	~ 85 kDa
Gene Name:	mutL homolog 1
Database Link:	<a href="#">Entrez Gene 17350 Mouse</a> <a href="#">Entrez Gene 81685 Rat</a> <a href="#">Entrez Gene 4292 Human</a> <a href="#">P40692</a>



[View online »](#)

**Background:**

DNA-mismatch repair (MMR) is an essential process in maintaining genetic stability. Lack of a functional DNA-mismatch repair pathway is a common characteristic of several different types of human cancers, either due to an MMR gene mutation or promoter methylation gene silencing. MLH1 is an integral part of the protein complex responsible for mismatch repair that is expressed in lymphocytes, heart, colon, breast, lung, spleen, testis, prostate, thyroid and gall bladder and is methylated in several ovarian tumors. Loss of MLH1 protein expression is associated with a mutated phenotype, microsatellite instability and a predisposition to cancer. In hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal dominant inherited cancer syndrome that signifies a high risk of colorectal and various other types of cancer, the MLH1 gene exhibits a pathogenic mutation. Certain cancer cell lines, including leukemia CCRF-CEM, colon HCT 116 and KM12, and ovarian cancers SK-OV-3 and IGROV-1, show complete deficiency of MLH1, while MLH1 is expressed in 60% of melanomas, 70% of noninvasive squamous cell carcinomas and 30% of invasive squamous cell carcinomas.

**Synonyms:**


DNA mismatch repair protein Mlh1, COCA2

**Protein Families:**

Druggable Genome

**Protein Pathways:**

Colorectal cancer, Endometrial cancer, Mismatch repair, Pathways in cancer

**Product images:**

Western blot (WB) analysis of MLH1 antibody (Cat.-No.: AP20490PU-N) in extracts from K562 cells.